506 related articles for article (PubMed ID: 18203948)
1. Progress in brain penetration evaluation in drug discovery and development.
Liu X; Chen C; Smith BJ
J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
[TBL] [Abstract][Full Text] [Related]
2. Strategies to optimize brain penetration in drug discovery.
Liu X; Chen C
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
Adenot M; Lahana R
J Chem Inf Comput Sci; 2004; 44(1):239-48. PubMed ID: 14741033
[TBL] [Abstract][Full Text] [Related]
4. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
Löscher W; Potschka H
Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
[TBL] [Abstract][Full Text] [Related]
5. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
[TBL] [Abstract][Full Text] [Related]
6. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.
Kikuchi R; de Morais SM; Kalvass JC
Drug Metab Dispos; 2013 Dec; 41(12):2012-7. PubMed ID: 24009309
[TBL] [Abstract][Full Text] [Related]
7. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
Reichel A
Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
[TBL] [Abstract][Full Text] [Related]
8. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
[TBL] [Abstract][Full Text] [Related]
9. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
[TBL] [Abstract][Full Text] [Related]
11. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
Adenot M; Perriere N; Scherrmann JM; Lahana R
Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
[TBL] [Abstract][Full Text] [Related]
12. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
Summerfield SG; Read K; Begley DJ; Obradovic T; Hidalgo IJ; Coggon S; Lewis AV; Porter RA; Jeffrey P
J Pharmacol Exp Ther; 2007 Jul; 322(1):205-13. PubMed ID: 17405866
[TBL] [Abstract][Full Text] [Related]
14. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.
Padowski JM; Pollack GM
Brain Res; 2011 Dec; 1426():1-17. PubMed ID: 22036081
[TBL] [Abstract][Full Text] [Related]
15. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
16. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
Liu X; Smith BJ; Chen C; Callegari E; Becker SL; Chen X; Cianfrogna J; Doran AC; Doran SD; Gibbs JP; Hosea N; Liu J; Nelson FR; Szewc MA; Van Deusen J
J Pharmacol Exp Ther; 2005 Jun; 313(3):1254-62. PubMed ID: 15743928
[TBL] [Abstract][Full Text] [Related]
17. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
18. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.
Linnet K; Ejsing TB
Eur Neuropsychopharmacol; 2008 Mar; 18(3):157-69. PubMed ID: 17683917
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
Wang Q; Rager JD; Weinstein K; Kardos PS; Dobson GL; Li J; Hidalgo IJ
Int J Pharm; 2005 Jan; 288(2):349-59. PubMed ID: 15620875
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.
Kaddoumi A; Choi SU; Kinman L; Whittington D; Tsai CC; Ho RJ; Anderson BD; Unadkat JD
Drug Metab Dispos; 2007 Sep; 35(9):1459-62. PubMed ID: 17591677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]